Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 10/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | TCF4 | P15884 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147884 | 0.88 | CTNNB1 (0.79) | CTNNB1AKR1B10AKR1B1TCF4KDM4E | |
| SCHEMBL18249664 | 0.87 | CTNNB1 (1.00) | CTNNB1TCF4KDM4E | |
| SCHEMBL18249657 | 0.85 | CTNNB1 (1.00) | CTNNB1AKR1B10AKR1B1TCF4KDM4E | |
| SCHEMBL18257902 | 0.84 | CTNNB1 (1.00) | CTNNB1TCF4KDM4E | |
| SCHEMBL1611668 | 0.82 | KMT2A (0.71) | CTNNB1AKR1B10AKR1B1KDM4E | |
| SCHEMBL20147875 | 0.81 | CTNNB1 (0.80) | CTNNB1TCF4KDM4E | |
| SCHEMBL20147874 | 0.81 | CTNNB1 (0.67) | CTNNB1TCF4KDM4E | |
| SCHEMBL20149529 | 0.80 | CTNNB1 (0.67) | CTNNB1TCF4KDM4E | |
| SCHEMBL18249633 | 0.80 | CTNNB1 (1.00) | CTNNB1TCF4 | |
| SCHEMBL20147882 | 0.80 | CTNNB1 (0.78) | CTNNB1TCF4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299123-A1 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-30 | — | — | US | disclosed |
| US-10273246-B2 | Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273246-B2 | Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH | 2018-05-17 | — | — | US | disclosed |
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH | 2018-05-17 | — | — | US | disclosed |
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH | 2018-05-17 | — | — | US | disclosed |
| WO-2016187050-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5]OXADIAZOLO[3',4':5,6] PYRAZIONO[2,3-B]INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187050-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5]OXADIAZOLO[3',4':5,6] PYRAZIONO[2,3-B]INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | CTNNB1, CTNNBL1, WNT3A | CTNNB1 1/4885AKR1B10 3701/4885AKR1B1 2973/4885 |
| US-20210299123-A1 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF | XIAP, BIRC5, TP53 | CTNNB1 1509/4885AKR1B10 3396/4885AKR1B1 2804/4885 |
| US-10273246-B2 | Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions | CTNNB1, CTNNBL1, WNT3A | CTNNB1 1/4885AKR1B10 3778/4885AKR1B1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.